The 20 best-performing stocks of 2022 according to reliable analysts
These stocks were not cherry-picked in hindsight: they are the ones the method would have selected using only info known by end of 2021 (price targets from reliable analysts in the prior ~90 days), then held unchanged for 12 months. A true point-in-time record.
🎯 JPI Fair -11% · vs S&P 500 -19% · +8.7 pts
| # | Stock | 12-month return |
|---|---|---|
| 1 | HAE Haemonetics | +48% |
| 2 | NBIX Neurocrine Biosciences | +40% |
| 3 | JAZZ Jazz Pharmaceuticals | +25% |
| 4 | BIIB Biogen | +15% |
| 5 | TBBK The Bancorp, Inc. | +12% |
| 6 | GKOS Glaukos Corp. | -2% |
| 7 | TPR Tapestry, Inc. | -6% |
| 8 | OLLI Ollie's Bargain Outlet | -8% |
| 9 | EXEL Exelixis | -12% |
| 10 | EAT Brinker International, Inc. | -13% |
| 11 | MAT Mattel | -17% |
| 12 | BBY Best Buy | -21% |
| 13 | SIG Signet Jewelers | -22% |
| 14 | KTB Kontoor Brands | -22% |
| 15 | PNFP Pinnacle Financial Partners | -23% |
| 16 | MRNA Moderna | -29% |
| 17 | SAM Boston Beer Company | -35% |
| 18 | XNCR Xencor Inc | -35% |
| 19 | GT Goodyear Tire and Rubber Company | -52% |
| 20 | SKYW SkyWest, Inc. | -58% |
⚡ JPI Risk + -10% · vs S&P 500 -19% · +9.3 pts
| # | Stock | 12-month return |
|---|---|---|
| 1 | OXY Occidental Petroleum | +117% |
| 2 | APA APA Corporation | +74% |
| 3 | NBIX Neurocrine Biosciences | +40% |
| 4 | JAZZ Jazz Pharmaceuticals | +25% |
| 5 | BIIB Biogen | +15% |
| 6 | OLLI Ollie's Bargain Outlet | -8% |
| 7 | EXEL Exelixis | -12% |
| 8 | EAT Brinker International, Inc. | -13% |
| 9 | UAL United Airlines Holdings | -14% |
| 10 | MAT Mattel | -17% |
| 11 | BBY Best Buy | -21% |
| 12 | KTB Kontoor Brands | -22% |
| 13 | IP International Paper | -26% |
| 14 | XPO XPO, Inc. | -28% |
| 15 | SAM Boston Beer Company | -35% |
| 16 | NCLH Norwegian Cruise Line Holdings | -41% |
| 17 | GM General Motors | -43% |
| 18 | CCL Carnival Corporation | -60% |
| 19 | PYPL PayPal | -62% |
| 20 | NEO NeoGenomics Laboratories, Inc. | -73% |
What if you'd kept following the method in 2023?
| Year | JPI Fair | S&P 500 |
|---|---|---|
| 2022 | -11% | -19% |
| 2023 | +32% | +24% |
| 2-year cumulative (if you kept going) | +17% | +0% |
💡 The takeaway — you have to accept the average or down years and stay in the method (sell, rebuy the newly recommended names). Whoever panics after a bad year misses the rebound. Discipline > emotion.
📊 See the full 11-year backtest → 🎯 Stocks to buy today →
FAQ
What were the best stocks to buy in 2022?
Per the JPI Fair method (targets from the ≥2 most reliable analysts per sector), the 20 stocks selected in early 2022 returned -10.8% on average over 12 months, vs -19.5% for the index. The best was HAE (Haemonetics) at +48%. See the full list above.
How were these 2022 stocks chosen?
With no hindsight: only from information known by end of 2021 (price targets from analysts with a real reliability track record on their sector), then held 12 months. A point-in-time backtest, not a hindsight pick.
Does this method actually work?
Over 11 years (2015-2025), the JPI Fair method returned +19.8%/yr vs +11.5% for the S&P 500 — +8.3 points a year, beating the index in 8 of 11 years. But it's lumpy (down years in 2018 and 2022) and risk-adjusted the edge is thinner. A quality signal, not a guarantee.
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 11 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email